Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International Multicenter Double-Blind Placebo-Controlled Comparative Randomized Trial of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) And BCD-100 (Anti-PD-1) Therapy Compared to BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

NCT03913923 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT03913923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03913923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International Multicenter Double-Blind Placebo-Controlled Comparative Randomized Trial of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) And BCD-100 (Anti-PD-1) Therapy Compared to BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma
Lead sponsor
Biocad
Phase
Phase 2
Overall status
Unknown status
Start date
July 1, 2019
Completion date
December 31, 2023
Enrollment
117 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, melanoma metastatic